Reza Mehrazin, MD
- ASSOCIATE PROFESSOR | Urology
Specialty:
UrologyResearch Topics:
Anti-Tumor Therapy, Cancer, Imaging, Kidney, Patient Care, Patient Centered Outcomes Research, Prostate, Robotic Surgery, Technology & InnovationDr. Reza Mehrazin is Associate Professor of Urology, Icahn School of Medicine at Mount Sinai. Dr. Mehrazin joined the surgical staff at Mount Sinai School of Medicine after completing a two-year Society of Urologic Oncology (SUO) accredited fellowship at a highly prestigious National Cancer Institute (NCI) designated cancer center, Fox Chase Cancer Center. Prior to his fellowship, he completed his general surgery internship and urology residency at University of Tennessee Health Science Center.
Dr. Mehrazin’s clinical expertise is in open, laparoscopic, and robotic surgical techniques for the treatment of various urologic cancers, which allows him to tailor a specific treatment plan based on individual patient need and preferences. He is one of the few urologists in the region who has extensive training and certified in performing minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life for patients with kidney cancer and bladder cancer. He performs both robotic (using da Vinci® technology) and open cystectomies with continent urinary diversion (new bladder), nephron-sparing (kidney preserving) partial nephrectomy, nerve-sparing prostatectomy, partial or total adrenalectomy, retroperitoneal lymph node dissection for testicular cancer, and endoscopic nephron-sparing management of patients with upper tract urothelial carcinomas. He also has a special clinical interest in the management of patients with metastatic and advanced kidney cancer with tumors extending into the surrounding organs or major vessels, as well as salvage bladder surgeries following radiation therapy.
His research interests revolve around novel clinical and surgical treatment of kidney and bladder cancer. Over 300 of his abstracts have been presented at international, national, and regional scientific meetings. He has authored and co-authored over 130 scientific papers which are published or currently in press in major, high impact journals.
In addition he has authored several text book chapters on robotic surgical techniques, kidney tumors, bladder cancer, prostate cancer, upper tract urothelial carcioma, and adrenal tumors. He is a member of editorial board for several medical journals and the chief editor of Genitourinary Sarcoma chapter of the American Urological Association. He is also the Director of Society of Urologic Oncology fellowship program at Mount Sinai Hospital.
He takes a multi-disciplinary approach and works closely with Medical Oncology and Radiation Oncology physicians at Mount Sinai Health Care System to deliver comprehensive care and support for each patient.
He is a member of the American Urological Association, American College of Surgeons, Society of Urologic Oncology and American Society of Clinical Oncology.
Dr. Mehrazin's Patients Stories:
Mets' Baseball Team voice Howie Rose, reveals bladder cancer battle
NewYork Post:
Member of New York Police Department with Kidney Cancer:
https://www.mountsinai.org/about/patient-stories/finding-the-best-doctor-through-a-best-friend
BLADDER CANCER
Dr. Mehrazin speaks about Robotic Cystectomy http://blog.mountsinai.org/blog/robotic-cystectomy-vs-open-cystectomy/
KIDNEY CANCER or Renal Cell Carcinoma:
NY Daily News:
Dr. Mehrazin discusses kidney cancer signs and symptoms of new advances in treatment http://www.nydailynews.com/life-style/daily-checkup-kidney-cancer-attention-article-1.2385577
Dr. Mehrazin comments discusses his research about close monitoring of renal tumors https://www.mountsinai.org/about/newsroom/2015/close-monitoring-of-renal-tumors-may-provide-alternative-to-surgery
Certifications
American Board of Urology
Clinical Focus
- Adrenal Cortical Carcinoma
- Adrenal Gland Tumors
- Adrenal Surgery
- Adrenalectomy
- Adrenalectomy-Laparoscopic Surgery
- Adrenalectomy-Open Surgery
- Adrenocortical Carcinoma
- Bladder Cancer
- Cystectomy
- Cystoscopy
- Evaluation of Kidney Mass
- Kidney Cancer
- Laparoscopy
- Lymph Node Biopsy
- Microscopic Hematuria
- Minimally Invasive Surgery
- Nephrectomy
- Penile Cancer
- Prostate Biopsy
- Prostate Cancer
- Prostate Cancer Second Opinion
- Prostate-Specific Antigen (PSA) Test
- Prostatectomy
- Pyeloplasty
- Radical Cystectomy
- Renal Mass
- Robotic Kidney Surgery
- Robotic Prostate Surgery
- Testicular Cancer
- Ureteroscopy
- Urology Second Opinion
Education
MD, Medical University of the Americas-Nevis
Internship, Surgery (General Surgery), University of Tennessee Health Sciences Center
Residency, Urology, University of Tennessee Health Sciences Center
Fellowship, Urologic Oncology, Fox Chase Cancer Center
-
2019
Castle Connolly Top Doctors -
2019
Super Doctors -
2017
Resident Teaching Award
· Dr. Mehrazin has clinical and laboratory research interests in identifying biomarkers, anticancer agents and cutting-edge technologies to improve long-term surgical and functional outcomes in patients with various urologic cancers.
“I understand the emotional burden that diagnosis of cancer can have on the patient and family members. I always would treat my patients as I would treatment my own family and friends. I understand quality of life is superbly important and would personalize treatment for each patient through extensive discussions and effective communication.”
Ito T, Abbosh PH, Mehrazin R, Tomaszewski JJ, Li T, Ginzburg S, Canter DJ, Greenberg RE, Viterbo R, Chen DY, Kutikov A, Smaldone MC, Uzzo RG. Surgical Apgar Score Predicts an Increased Risk For Major Complications and Death Following Renal Mass Excision. The Journal of urology 2014 Nov;.
Mehrazin R, Galsky MD. Kidney cancer: Systemic therapy-differentiating the achievable from the achieved. Nature reviews. Urology 2015 Jan;.
Mehrazin R, Galsky MD. Kidney cancer: Systemic therapy-differentiating the achievable from the achieved. Nature reviews. Urology 2015 Jan;.
Mehrazin R, Piotrowski Z, Egleston B, Parker D, Tomaszweski JJ, Smaldone MC, Abbosh PH, Ito T, Bloch P, Iffrig K, Bilusic M, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, Kutikov A. Is extended pharmacologic venous thromboembolism prophylaxis uniformly safe after radical cystectomy?. Urology 2014 Nov; 84(5).
Mehrazin R, Smaldone M, Kutikov A, Li T, Tomaszewski J, Canter D, Viterbo R, Greenberg R, Chen DY, Uzzo R, Uzzo RG. Growth Kinetics and Short Term Outcomes of cT1b and cT2 Renal Masses Under Active Surveillance. The Journal of Urology 2014 September; 192: 659-664.
Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, Tulin A, Uzzo RG, Kolenko VM, Chen DY, Greenberg RE, Canter D, Smaldone MC, Kutikov A. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. British journal of cancer 2014 Feb; 110(4).
Jabaji R, Palazzi KL, Mehrazin R, Cohen SA, Masterson JH, Woo JR, Lee H, Liss MA, Kopp RP, Wang S, Stroup SP, Patterson AL, L'Esperance JO, Derweesh IH. Determinants of renal functional decline after open partial nephrectomy: a comparison of warm, cold, and non-ischemic modalities. The Canadian journal of urology 2014 Feb; 21(1).
Mehrazin R, Smaldone MC, Kutikov A, Li T, Tomaszewski JJ, Canter DJ, Viterbo R, Greenberg RE, Chen DY, Uzzo RG, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Growth Kinetics and Short-Term Outcomes of cT1b and cT2 Renal Masses under Active Surveillance. The Journal of urology 2014 Mar;.
Bagrodia A, Kopp RP, Mehrazin R, Lee HJ, Liss MA, Jabaji R, Kane CJ, Wake RW, Patterson AL, Wan JY, Derweesh IH. Impact of renal surgery for cortical neoplasms on lipid metabolism. BJU international 2014 Mar;.
Bagrodia A, Kopp RP, Mehrazin R, Lee HJ, Liss MA, Jabaji R, Kane CJ, Wake RW, Patterson AL, Wan JY, Derweesh IH. Impact of renal surgery for cortical neoplasms on lipid metabolism. BJU international 2014 Mar;.
Tomaszewski JJ, Uzzo RG, Kutikov A, Hrebinko K, Mehrazin R, Corcoran A, Ginzburg S, Viterbo R, Chen DY, Greenberg RE, Smaldone MC. Assessing the burden of complications after surgery for clinically localized kidney cancer by age and comorbidity status. Urology 2014 Apr; 83(4).
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Jun; 32(18).
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC, Patterson AL, L'Esperance JO, Derweesh IH. Care Transitions between Hospitals Are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer. The Journal of urology 2014 May;.
Tomaszewski JJ, Uzzo RG, Kocher N, Li T, Manley B, Mehrazin R, Ito T, Abbosh P, Viterbo R, Chen DY, Greenberg RE, Canter D, Smaldone MC, Kutikov A. Patients with anatomically . Urologic oncology 2014 Jun;.
Tomaszewski JJ, Smaldone MC, Mehrazin R, Kocher N, Ito T, Abbosh P, Baber J, Kutikov A, Viterbo R, Chen DY, Canter DJ, Uzzo RG. Anatomic complexity quantitated by nephrometry score is associated with prolonged warm ischemia time during robotic partial nephrectomy. Urology 2014 Aug; 84(2).
Tomaszewski JJ, Smaldone MC, Cung B, Li T, Mehrazin R, Kutikov A, Canter DJ, Viterbo R, Chen DY, Greenberg RE, Uzzo RG, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, Kutikov A. Internal validation of the renal pelvic score: a novel marker of renal pelvic anatomy that predicts urine leak after partial nephrectomy. Urology 2014 Aug; 84(2).
Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzberg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic oncology 2014 Jul;.
Kopp RP, Mehrazin R, Palazzi KL, Liss MA, Jabaji R, Mirheydar HS, Lee HJ, Patel N, Elkhoury F, Patterson AL, Derweesh IH, Uzzo RG. Survival Outcomes after Radical and Partial Nephrectomy for Clinical T2 Renal Tumors Categorized by RENAL Nephrometry Score. BJU international 2013 Nov;.
Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzberg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. .;.
Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer biology & therapy 2015 Mar;.
Mehrazin R, Smaldone MC, Egleston B, Tomaszewski JJ, Concodora CW, Ito TK, Abbosh PH, Chen DY, Kutikov A, Uzzo RG. Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?. Urologic oncology 2015 Mar;.
Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Jun;.
Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Jun;.
Liaw BC, Mehrazin R, Baker C, Sfakianos JP, Tsao CK. Management of Atypical Renal Cell Carcinomas. Current treatment options in oncology 2017 Sep; 18(10).
Chen A, Chong J, Si Q, Haines K, Mehrazin R. Robotic approach to resection of villous adenoma of the urachus: a case report and literature review. Journal of robotic surgery 2017 Sep;.
Attalla K, Kent M, Waingankar N, Mehrazin R. Robotic-assisted radical cystectomy versus open radical cystectomy for management of bladder cancer: review of literature and randomized trials. Future oncology (London, England) 2017 Jun; 13(13).
Ghanney EC, Cavallo JA, Levin MA, Reddy R, Bander J, Mella M, Stone J, Schwartz M, Haines K, Gidwani U, Mehrazin R. Renal cell carcinoma with inferior vena cava thrombus extending to the right atrium diagnosed during pregnancy. Therapeutic advances in urology 2017 Dec; 9(6).
Attalla K, Haines K, Labow D, Mehrazin R. Squamous Cell Carcinoma of the Renal Pelvis: Atypical Presentation of a Rare Malignancy. Urology case reports 2017 Jul; 13.
Berquist SW, Lee HJ, Hamilton Z, Bagrodia A, Hassan AE, Beksaç AT, Dufour CA, Wang S, Mehrazin R, Patterson A, Derweesh IH. Statin utilization improves oncologic and survival outcomes in patients with dyslipidemia and surgically treated renal cell carcinoma. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2017 Oct; 69(5).
Hassan AR, Raheem OA, Berquist S, Beksac AT, Bloch A, Field C, Lee HJ, Mehrazin R, Holden M, McDONALD M, Hamilton Z, Liss M, Derweesh IH. Comparison of laparoendoscopic single-site (LESS) and multiport laparoscopic radical nephrectomy for clinical T1b and T2a renal masses. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2017 Mar;.
Mohamed NE, Pisipati S, Lee CT, Goltz HH, Latini DM, Gilbert FS, Wittmann D, Knauer CJ, Mehrazin R, Sfakianos JP, McWilliams GW, Quale DZ, Hall SJ. Unmet informational and supportive care needs of patients following cystectomy for bladder cancer based on age, sex, and treatment choices. Urologic oncology 2016 Dec; 34(12).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Mehrazin did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.